Allergan Acquires Anterios

 

DUBLIN and NEW YORK, Jan. 7, 2016Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential development and commercialization milestone payments related to NDS™, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.

In addition to NDS™, Allergan has acquired global rights to ANT-1207, an investigational topical formulation botulinum toxin type A in development for the potential treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.

Subscribe to get the latest news